Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.

Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Darling TN, Burton-Akright J, Bagheri M, Dombi E, Gruber A, Jarosinski PF, Martin S, Nathan N, Paul SM, Savage RE, Wolters PL, Schwartz B, Widemann BC, Biesecker LG.

Am J Hum Genet. 2019 Mar 7;104(3):484-491. doi: 10.1016/j.ajhg.2019.01.015. Epub 2019 Feb 22.

2.

Influence of electron beam irradiation on water-saturated biodiesel.

Grabowski P, JarosiƄski P, Szajerski P, Gwardiak H.

J Radioanal Nucl Chem. 2018;318(2):1401-1408. doi: 10.1007/s10967-018-6153-1. Epub 2018 Aug 24.

3.

Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Brooks KM, Jarosinski P, Hughes T, Kang E, Shah NN, Gall JBL, Hickstein DD, De Ravin SS, George JM, Kumar P.

J Clin Pharmacol. 2018 Mar;58(3):332-339. doi: 10.1002/jcph.1049. Epub 2017 Dec 14.

4.

Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb.

5.

Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Lestner JM, Groll AH, Aljayyoussi G, Seibel NL, Shad A, Gonzalez C, Wood LV, Jarosinski PF, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7340-7346. doi: 10.1128/AAC.01427-16. Print 2016 Dec.

6.

Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.

Moriyama B, Jarosinski PF, Figg WD, Henning SA, Danner RL, Penzak SR, Wayne AS, Walsh TJ.

Pharmacotherapy. 2013 Mar;33(3):e19-22. doi: 10.1002/phar.1192. Epub 2013 Feb 11.

7.

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, Walsh TJ.

Mycoses. 2012 Jul;55(4):290-7. doi: 10.1111/j.1439-0507.2011.02158.x. Epub 2011 Nov 29. Review.

8.

A constipation assessment scale for use in pediatric oncology.

Woolery M, Carroll E, Fenn E, Wieland H, Jarosinski P, Corey B, Wallen GR.

J Pediatr Oncol Nurs. 2006 Mar-Apr;23(2):65-74.

PMID:
16476780
9.

Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.

Roden MM, Nelson LD, Knudsen TA, Jarosinski PF, Starling JM, Shiflett SE, Calis K, DeChristoforo R, Donowitz GR, Buell D, Walsh TJ.

Clin Infect Dis. 2003 May 15;36(10):1213-20. Epub 2003 May 8.

PMID:
12746764
10.

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.

Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jarosinski P, Walsek CM, Brouwers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, Wood LV.

J Infect Dis. 1999 Sep;180(3):626-40.

PMID:
10438349
11.

Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W.

Antimicrob Agents Chemother. 1998 Sep;42(9):2391-8.

12.

Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.

Mueller BU, Anderson BD, Farley MQ, Murphy R, Zuckerman J, Jarosinski P, Godwin K, McCully CL, Mitsuya H, Pizzo PA, Balis FM.

Antimicrob Agents Chemother. 1998 Jul;42(7):1815-8.

13.

A phase I/II study of the protease inhibitor indinavir in children with HIV infection.

Mueller BU, Sleasman J, Nelson RP Jr, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwerski S, Sei S, Wood LV, Zeichner S, Pizzo PA.

Pediatrics. 1998 Jul;102(1 Pt 1):101-9.

PMID:
9651421
14.

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.

Mueller BU, Nelson RP Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, Wood LV, Zeichner S, Katz TT, Higham C, Aker D, Edgerly M, Jarosinski P, Serchuck L, Whitcup SM, Pizzuti D, Pizzo PA.

Pediatrics. 1998 Mar;101(3 Pt 1):335-43.

PMID:
9480994
15.

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Walsh TJ, Whitcomb P, Piscitelli S, Figg WD, Hill S, Chanock SJ, Jarosinski P, Gupta R, Pizzo PA.

Antimicrob Agents Chemother. 1997 Sep;41(9):1944-8.

16.

Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.

Wexler LH, DeLaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L, Jacobson J, Jarosinski P, Hijazi YM, Balis FM, Horowitz ME.

Cancer. 1996 Aug 15;78(4):901-11. Erratum in: Cancer 1997 Feb 15;79(4):867.

PMID:
8756388
17.

Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.

Wexler LH, Weaver-McClure L, Steinberg SM, Jacobson J, Jarosinski P, Avila N, Pizzo PA, Horowitz ME.

J Clin Oncol. 1996 Mar;14(3):901-10.

PMID:
8622038
18.

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, Horowitz ME.

J Clin Oncol. 1996 Feb;14(2):362-72.

PMID:
8636745
19.

A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.

Ho PT, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L, Izraeli S, Balis FM.

Cancer. 1995 Dec 15;76(12):2557-64.

PMID:
8625085
20.

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem.

Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, et al.

J Clin Oncol. 1995 Jan;13(1):165-76.

PMID:
7799016
21.

Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection.

Mueller BU, Butler KM, Stocker VL, Balis FM, Brouwers P, Jarosinski P, Husson RN, Lewis LL, Venzon D, Pizzo PA.

Pediatrics. 1994 Nov;94(5):724-31.

PMID:
7936903
22.

Drug interaction of terfenadine and carbamazepine.

Hirschfeld S, Jarosinski P.

Ann Intern Med. 1993 Jun 1;118(11):907-8. No abstract available.

PMID:
8480971
23.

Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.

Husson RN, Chung Y, Mordenti J, Butler KM, Chen S, Duliege AM, Brouwers P, Jarosinski P, Mueller BU, Ammann A, et al.

J Pediatr. 1992 Oct;121(4):627-33.

PMID:
1357124
24.

Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.

Butler KM, De Smet MD, Husson RN, Mueller B, Manjunath K, Montrella K, Lovato G, Jarosinski P, Nussenblatt RB, Pizzo PA.

J Pediatr. 1992 Mar;120(3):483-6.

PMID:
1311378
25.

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P, et al.

J Infect Dis. 1992 Jan;165(1):99-104.

PMID:
1727902
26.

Precipitation of ondansetron in alkaline solutions.

Jarosinski PF, Hirschfeld S.

N Engl J Med. 1991 Oct 31;325(18):1315-6. No abstract available.

PMID:
1656257
27.

Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection.

Lam NP, Kennedy PE, Jarosinski PF, Gallelli JF.

Am J Hosp Pharm. 1991 Feb;48(2):280-2.

PMID:
2003500
28.

Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.

Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, el-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H, et al.

N Engl J Med. 1991 Jan 17;324(3):137-44.

29.

Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.

Pizzo PA, Butler K, Balis F, Brouwers E, Hawkins M, Eddy J, Einloth M, Falloon J, Husson R, Jarosinski P, et al.

J Pediatr. 1990 Nov;117(5):799-808.

PMID:
2172501
30.

Increasing usage of systemic antifungal agents.

Walsh TJ, Jarosinski PF, Fromtling RA.

Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):37-40. No abstract available.

PMID:
2331848
31.

Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.

Balis FM, Pizzo PA, Eddy J, Wilfert C, McKinney R, Scott G, Murphy RF, Jarosinski PF, Falloon J, Poplack DG.

J Pediatr. 1989 May;114(5):880-4.

PMID:
2715903
32.

Stability of concentrated trimethoprim-sulfamethoxazole admixtures.

Jarosinski PF, Kennedy PE, Gallelli JF.

Am J Hosp Pharm. 1989 Apr;46(4):732-7.

PMID:
2785757
33.

The pharmacokinetics of zidovudine administered by continuous infusion in children.

Balis FM, Pizzo PA, Murphy RF, Eddy J, Jarosinski PF, Falloon J, Broder S, Poplack DG.

Ann Intern Med. 1989 Feb 15;110(4):279-85.

PMID:
2643914
34.

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection.

Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, Wolters P, Brouwers P, Jarosinski P, Rubin M, et al.

N Engl J Med. 1988 Oct 6;319(14):889-96.

PMID:
3166511
35.

Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.

Jarosinski PF, Moscow JA, Alexander MS, Lesko LJ, Balis FM, Poplack DG.

J Pediatr. 1988 Jun;112(6):996-9. No abstract available.

PMID:
3163735
36.

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R, Magrath I.

J Clin Oncol. 1987 Aug;5(8):1191-8.

PMID:
3114435
37.

The importance of pharmacist surveillance in a unit dose drug distribution system.

Jarosinski PF.

Hosp Pharm. 1978 Sep;13(9):491-2, 496, 498.

PMID:
10238815

Supplemental Content

Loading ...
Support Center